ASBESTOS-ASSOCIATED NEOPLASMS OF B-CELL LINEAGE

被引:54
作者
KAGAN, E
JACOBSON, RJ
YEUNG, KY
HAIDAK, DJ
NACHNANI, GH
机构
[1] GEORGETOWN UNIV,SCH MED,DEPT MED,DIV ONCOL,WASHINGTON,DC 20007
[2] GEORGETOWN UNIV,MED CTR,DEPT MED,DIV HEMATOL & ONCOL,WASHINGTON,DC 20007
[3] SO MARYLAND HOSP,DEPT INTERNAL MED,CLINTON,MD
关键词
D O I
10.1016/0002-9343(79)90408-X
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Three different neoplasms of B cell lineage, chronic lymphocytic leukemia, immunoglobulin A (IgA) myeloma and immunoglobulin G (IgG) myeloma were detected in three patients who had heavy occupational exposure to asbestos dust. Two of the patients had coexistent pulmonary asbestosis, whereas the third patient had a pleural mesothelioma subsequent to his initial presentation with myeloma. Defective cell-mediated immunity and hyperactivity of B cell function have previously been noted in patients with asbestosis. We suggest the possibility that these asbestos-related immunologic derangements may predispose to the development of immunoproliferative and lymphoproliferative neoplasms, since such tumors have been observed in a variety of other settings, characterized by protracted hyperactivity of the immune system. © 1979.
引用
收藏
页码:325 / 330
页数:6
相关论文
共 27 条
[1]  
BECKLAKE MR, 1976, AM REV RESPIR DIS, V114, P187
[2]   PRODROMAL DYSIMMUNITY IN CANCER - PATHOPHYSIOLOGY OF PRENEOPLASTIC AND PERINEOPLASTIC IMMUNE DEFICIENCY DISORDERS THAT MAY REPRESENT SYNDROMES OF TRANSITION FROM DYSIMMUNITY TO CANCER [J].
DECARVALHO, S .
ONCOLOGY, 1973, 28 (01) :1-34
[3]   ASBESTOS-DUST EXPOSURES AT VARIOUS LEVELS AND MORTALITY [J].
ENTERLINE, PE ;
KENDRICK, MA .
ARCHIVES OF ENVIRONMENTAL HEALTH, 1967, 15 (02) :181-+
[4]  
GERBER MA, 1970, AM J CLIN PATHOL, V53, P204
[5]  
GLEICHMANN E, 1972, JNCI-J NATL CANCER I, V49, P793
[6]  
GRIEVE JM, 1967, CANCER CAPE DIVISION, P82
[7]  
HASLAM PL, 1978, CLIN EXP IMMUNOL, V31, P178
[8]   PATHOLOGIC CONDITIONS ASSOCIATED WITH PLASMA-CELL DYSCRASIAS - STUDY OF 806 CASES [J].
ISOBE, T ;
OSSERMAN, EF .
ANNALS OF THE NEW YORK ACADEMY OF SCIENCES, 1971, 190 :507-&
[9]  
KAGAN E, 1977, CLIN EXP IMMUNOL, V28, P261
[10]  
KAGAN E, 1977, CLIN EXP IMMUNOL, V28, P268